Thermo Fisher Scientific Inc. $TMO Shares Sold by Segment Wealth Management LLC

Segment Wealth Management LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,559 shares of the medical research company’s stock after selling 141 shares during the period. Segment Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $632,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mondrian Investment Partners LTD lifted its stake in shares of Thermo Fisher Scientific by 146.1% in the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock valued at $106,738,000 after purchasing an additional 127,357 shares in the last quarter. Caledonia Investments PLC boosted its position in shares of Thermo Fisher Scientific by 11.5% in the second quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after buying an additional 11,500 shares during the period. Foresight Group Ltd Liability Partnership boosted its position in shares of Thermo Fisher Scientific by 3,242.7% in the first quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after buying an additional 56,747 shares during the period. Advisors Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 6.7% in the first quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company’s stock worth $63,201,000 after buying an additional 7,967 shares during the period. Finally, New England Research & Management Inc. boosted its position in shares of Thermo Fisher Scientific by 28.6% in the second quarter. New England Research & Management Inc. now owns 2,548 shares of the medical research company’s stock worth $1,033,000 after buying an additional 567 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Up 3.6%

Shares of NYSE TMO opened at $543.88 on Friday. The stock’s 50 day moving average price is $482.58 and its two-hundred day moving average price is $447.27. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The stock has a market capitalization of $205.37 billion, a P/E ratio of 31.46, a PEG ratio of 2.95 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the prior year, the firm posted $5.37 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.95%.

Analyst Ratings Changes

TMO has been the subject of several analyst reports. Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Hsbc Global Res downgraded Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. Barclays boosted their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research note on Thursday. Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a research note on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and an average price target of $585.37.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.